AB154 Combined With AB122 for Recurrent Glioblastoma

NCT04656535 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: Zimberelimab
DRUG: Domvanalimab
DRUG: Placebo

Sponsor

Yale University

Collaborators

[object Object]
[object Object]